BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide derived from a protein found in gastric juice. In research settings it is studied for its role in tendon, ligament and gut tissue repair, angiogenesis and the modulation of inflammatory signalling.

TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring protein involved in actin regulation. Research explores its role in cell migration, new blood vessel formation and systemic tissue remodelling after injury.

Why are BPC-157 and TB-500 combined in the 'Wolverine Stack'?

The two peptides are studied for complementary mechanisms: BPC-157 is investigated for localised repair of tendon, ligament and gut tissue, while TB-500 is investigated for systemic cell migration and vascularisation. Combining them is commonly referred to as the 'Wolverine Stack' in recovery literature.

Are BPC-157 and TB-500 legal in the UK?

Both are supplied through OXVALON for research purposes only, in line with UK regulations. Any therapeutic use is arranged separately through Dr Vahe Clinic under physician supervision, with prescriptions where required.

Are BPC-157 and TB-500 banned in sport?

Yes. Both peptides appear on the World Anti-Doping Agency prohibited list. Competitive athletes subject to anti-doping testing should not use them.

How long is a typical recovery research protocol?

Published research protocols commonly run in four to eight week blocks followed by a review period. Dosing, duration and suitability must be determined by a qualified physician — never self-directed.

Peptide Education

BPC-157 and TB-500: A Guide to Peptides for Recovery

A physician-informed overview of the two most researched recovery peptides — what each is studied for, why they are combined as the “Wolverine Stack”, and what UK law and anti-doping rules require you to know.

For research purpose only · Physician-supervised use only

BPC-157: localised tissue repair

BPC-157 is a stable 15-amino-acid sequence isolated from human gastric juice. Preclinical research has focused on its influence on the healing of tendon, ligament, muscle and intestinal tissue, largely via upregulation of growth-factor receptors and the promotion of angiogenesis — the formation of new blood vessels that carry oxygen and nutrients into damaged tissue.

Animal models have repeatedly examined its effect on tendon-to-bone healing and on inflammatory bowel conditions. It is also studied for its interaction with the nitric-oxide pathway, which may explain the vascular effects reported across several independent studies.

TB-500: systemic remodelling

TB-500 is the synthetic form of the active region of Thymosin Beta-4, a protein present in nearly all human cells and in high concentration at wound sites. Its primary studied mechanism is actin regulation — the process that allows repair cells to migrate towards injured tissue.

Where BPC-157 research skews local and structural, TB-500 research skews systemic: cell migration, flexibility of scar tissue, and vascularisation across a wider area rather than at a single site.

The 'Wolverine Stack': why they are studied together

The combination is nicknamed the Wolverine Stack because the two mechanisms are complementary rather than duplicative. BPC-157 is investigated for the structural repair of a specific injury site; TB-500 is investigated for the systemic recruitment of repair cells and improved blood supply feeding that site.

In practice, research protocols run the two in parallel over a defined block, then reassess. The rationale is coverage of both the local and the systemic side of tissue recovery within the same window.

Inflammation and recovery

Both peptides are studied for their effect on inflammatory signalling. The goal in the research literature is not to abolish inflammation — which is a necessary part of healing — but to shorten the phase in which inflammation stalls repair, so that remodelling can begin sooner.

This is why the pairing appears most often in soft-tissue injury research: chronic tendinopathy, ligament strain, and post-surgical recovery, where a prolonged inflammatory phase is the limiting factor.

Safety, supervision and anti-doping

Neither BPC-157 nor TB-500 is licensed as a medicine in the UK. Both are supplied by OXVALON for research purposes only, and any therapeutic protocol must be designed, prescribed and monitored by a qualified physician.

Both compounds are prohibited by the World Anti-Doping Agency. Athletes subject to testing should not use them under any circumstances. Anyone considering a protocol should first arrange a clinical consultation, including baseline blood work.

Speak to a physician about a recovery protocol

Peptide protocols at Dr Vahe Clinic are designed, prescribed and monitored by UK doctors, with baseline blood work and scheduled reviews.

Book a peptide consultation